Key Takeaways PCSA surged 122.3% after a phase II update from its NGC-Cap breast cancer study.Processa Pharmaceuticals reported higher exposure to cancer-killing metabolites versus Xeloda monotherapy.PCSA said tolerability was comparable, with far lower FBAL exposure and only mild side effects.Shares of Processa Pharmaceuticals (PCSA) surged 122.3% on Wednesday after the company provided an encouraging clinical update on its ongoing mid-stage study evaluating its investigational candidate NGC-Cap in patient ...